A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

NCT05261269 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-negative Metastatic Breast Cancer

Interventions

DRUG: DAN-222
DRUG: Niraparib

Sponsor

Dantari, Inc.